Nkarta, Inc. (NKTX)
NASDAQ:NKTX
NKTX Stock Chart & Stats
$2.13
-$0.05(-2.07%)
At close: 4:00 PM EST
$2.13
-$0.05(-2.07%)
Day’s Range― - ―
52-Week Range$1.42 - $2.81
Previous CloseN/A
Volume369.36K
Average Volume (3M)676.42K
Market Cap
$152.56M
Enterprise Value$188.79M
Total Cash (Recent Filing)$276.28M
Total Debt (Recent Filing)$76.42M
Price to Earnings (P/E)―
Beta1.04
Next Earnings
May 07, 2026EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding71,029,510
10 Day Avg. Volume628,865
30 Day Avg. Volume676,424
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)0.44
Price to Sales (P/S)0.00
P/FCF Ratio-1.52
Enterprise Value/Market Cap1.24
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-83.65
Enterprise Value/Ebitda-1.85
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.22
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Data Integration Across StudiesAbility to pool data from the two trials supports more robust dose-escalation analyses and may shorten the time to identify optimal dosing for multiple indications.
Regulatory And Trial DesignAgreement with the regulator to remove patient-by-patient stagger and permit a 3+3 dose-escalation framework enables simultaneous enrollment within cohorts, which can accelerate dose-finding milestones.
Safety Oversight ConsolidationCombining both studies under a single independent Data and Safety Monitoring Board centralizes safety review and can speed unified decisions on dose escalation and protocol adjustments.
Bears Say
Conditioning Regimen ChallengesShift to a fludarabine/cyclophosphamide conditioning regimen was prompted by prior incomplete B-cell depletion, indicating earlier protocol limitations that may complicate efficacy interpretation and require further adjustments.
Financial Performance PressureA reported quarterly net loss underscores ongoing operating losses that could heighten funding needs or dilute valuation if additional capital is required.
Safety SignalsReports of deep B-cell aplasias in patients create material safety concerns that could lead to increased monitoring, protocol modifications, or regulatory attention.
Nkarta News
NKTX FAQ
What was Nkarta, Inc.’s price range in the past 12 months?
Nkarta, Inc. lowest stock price was $1.42 and its highest was $2.81 in the past 12 months.
What is Nkarta, Inc.’s market cap?
Nkarta, Inc.’s market cap is $152.56M.
When is Nkarta, Inc.’s upcoming earnings report date?
Nkarta, Inc.’s upcoming earnings report date is May 07, 2026 which is in 41 days.
How were Nkarta, Inc.’s earnings last quarter?
Nkarta, Inc. released its earnings results on Mar 25, 2026. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.31 by -$0.06.
Is Nkarta, Inc. overvalued?
According to Wall Street analysts Nkarta, Inc.’s price is currently Overvalued.
Does Nkarta, Inc. pay dividends?
Nkarta, Inc. does not currently pay dividends.
What is Nkarta, Inc.’s EPS estimate?
Nkarta, Inc.’s EPS estimate is -0.36.
How many shares outstanding does Nkarta, Inc. have?
Nkarta, Inc. has 71,029,510 shares outstanding.
What happened to Nkarta, Inc.’s price movement after its last earnings report?
Nkarta, Inc. reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.31. Following the earnings report the stock price went up 0.469%.
Which hedge fund is a major shareholder of Nkarta, Inc.?
Currently, no hedge funds are holding shares in NKTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nkarta Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bullish
NKTX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 125.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $65.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.5%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Positive
20 days / 200 days
Momentum
48.95%
12-Months-Change
Fundamentals
Return on Equity
-27.69%
Trailing 12-Months
Asset Growth
-19.70%
Trailing 12-Months
Company Description
Nkarta, Inc.
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
NKTX Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Ownership Overview
Currently, No data available
---